ライフサイエンスコーパス: fibroid

1 enriched according to the size of a uterine fibroid.

2 vessels with decreased diameters within the fibroid.

3 Of 5,023 participants, 11% had a fibroid.

4 pathway] is aberrantly expressed in uterine fibroids.

5 l for a gene that is misexpressed in uterine fibroids.

6 lar matrix deposition, a hallmark of uterine fibroids.

7 n several early-life factors and early-onset fibroids.

8 uterine fibroids and reduced the size of the fibroids.

9 urements to assess endometrial thickness and fibroids.

10 Of 956 eligible women, 251 (26.3%) had fibroids.

11 of the 2 collections and the risk of uterine fibroids.

12 at regular exercise might help women prevent fibroids.

13 fter focused ultrasound treatment of uterine fibroids.

14 ion may suggest possible pathways to prevent fibroids.

15 ence of myometrial perfusion defects and new fibroids.

16 might be useful in the treatment of uterine fibroids.

17 of the molecular basis of the common uterine fibroids.

18 an women with no prior clinical diagnosis of fibroids.

19 -Mendelian manifestation of isolated uterine fibroids.

20 d elective abortion were not associated with fibroids.

21 2% of participants with serology results had fibroids.

22 ly larger fibroids than unexposed women with fibroids.

23 er's report), of whom 345 were found to have fibroids.

24 soy formula feeding and ultrasound-detected fibroids.

25 ing the molecular characteristics of uterine fibroids.

26 elied on self-report of clinically diagnosed fibroids.

27 modestly enlarged uterus with three uterine fibroids.

28 s and a visual lack of methylene blue in the fibroids.

29 rovides an excellent option to treat uterine fibroids.

30 ive and safe in treating symptomatic uterine fibroids.

31 egulator REST in the pathogenesis of uterine fibroids.

32 -2)-8.10(-5)) with the risk and/or growth of fibroids.

33 32% increase in the diameter of the largest fibroid (95% CI: 6%, 65%) and a 127% increase in total t

34 , and location but was stronger for multiple fibroids (adjusted risk ratio = 0.75, 95% confidence int

35 ge at menarche was inversely associated with fibroids (adjusted risk ratio = 0.87, 95% confidence int

36 Greater than 25% residual enhancement of a fibroid after embolization was considered an incomplete

37 Volume changes in treated fibroids after 6 months were compared with volume change

38 , sonohysterography depicted small submucous fibroids amenable to hysteroscopic myomectomy (n = 5), a

39 ife and childhood exposures with early-onset fibroids among black women and compared the results with

40 udy was to identify risk factors for uterine fibroids among women undergoing tubal sterilization.

41 mula feeding and ultrasound-detected uterine fibroids among young African-American women with no prio

42 A dominant submucosal fibroid and ischemia greater than or equal to 90% had gr

43 The volume of treated fibroid and nonperfused volume (NPV) were calculated wit

44 sociated with clinically significant uterine fibroids and aggressive renal tumors.

45 y relationships between drug distribution in fibroids and between vasculature characteristics, collag

46 tiologically implicated in diabetes, uterine fibroids and cancer.

47 results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of ho

48 domly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 mon

49 commonly performed procedure for symptomatic fibroids and has the lowest rate of reintervention (comp

50 en aged 40 years with a diagnosis of uterine fibroids and no desire for future pregnancy was followed

51 nalysis comparing representative sections of fibroids and normal myometrium showed a smaller number o

52 controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids.

53 ein, this article will discuss the nature of fibroids and their diagnosis, pharmacotherapy, surgical

54 n drug delivery for the treatment of uterine fibroids and tumors of similar composition.

55 e compared with volume changes in nontreated fibroids and with MR-based thermal dose estimates.

56 (mean age, 35.9 years +/- 4.8) with uterine fibroids and/or adenomyosis who were unable to conceive.

57 ong 5,512 participants, 10.4% had at least 1 fibroid, and 10.8% experienced a miscarriage.

58 egrees of volume reduction of the uterus and fibroid, and extents of symptom change.

59 the uterine fibroid, dominant (ie, largest) fibroid, and percentage of perfusion measurements from e

60 or age, BMI, race, family history of uterine fibroids, and isoflavone excretion, this trend remained

61 Parity, diabetes, fibroids, and poor social support were associated with p

62 a have suggested a possible association with fibroids, and serology for HSV-2 is much more sensitive

63 omatous polyps, five had hyperplasia, 11 had fibroids, and three had endometritis.

64 have >/= 2 tumors than unexposed women with fibroids (aPR 1.0, 95% CI: 0.7, 1.6).

65 Often, fibroids are asymptomatic and require no treatment.

66 Uterine fibroids are common tumors that can cause heavy menstrua

67 Uterine fibroids are hormonally responsive; estradiol and proges

68 Uterine leiomyomata (fibroids) are common and clinically important tumors, bu

69 Uterine leiomyomata (fibroids) are hormonally responsive tumors, but little i

70 Uterine leiomyomata (fibroids) are the leading cause of hysterectomy in the U

71 Uterine leiomyomas (or fibroids) are the most common tumors in women of reprodu

72 Uterine leiomyomata, or fibroids, are benign tumors of the uterine myometrium th

73 Uterine leiomyomata (UL), also known as fibroids, are the most common pelvic tumors in women of

74 e with incomplete infarction of the dominant fibroid at 3 years to determine extents of infarction, d

75 had intact uteri and no history of cancer or fibroids at enrollment in 1989.

76 Utilities for uterine fibroids before and after treatment were obtained with t

77 ate for the treatment of symptomatic uterine fibroids before surgery are uncertain.

78 ate for the treatment of symptomatic uterine fibroids before surgery are unclear.

79 Uterine leiomyomata (fibroids), benign neoplasms of the smooth muscle, are a

80 maging at higher magnification revealed that fibroid blood vessels were indeed perfused and stained w

81 Black women have a greater fibroid burden than whites, yet no study has systematica

82 d on self-report of a physician diagnosis of fibroids by the age of 30 years (n = 561).

83 ne collections (48 h apart) from 170 uterine fibroid cases and 173 controls were analyzed for isoflav

84 suggests that molecular characteristics of a fibroid changes with size.

85 ed the relationship between age at menarche, fibroid characteristics, and race.

86 y mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma

87 Patients whose fibroids demonstrated an NPV of at least 20% also experi

88 f an association between age at menarche and fibroid development (regardless of characteristics), dem

89 rts a possible role of early-life factors in fibroid development.

90 been hypothesized to play a role in uterine fibroid development.

91 ies [3.9%]), the ovarian artery supplied the fibroids directly.

92 Two readers compared the uterine fibroid, dominant (ie, largest) fibroid, and percentage

93 state study that systematically screened for fibroids during very early pregnancy.

94 zation (mean score, 14; 95% CI: 11, 18), and fibroid embolization (mean score, 12; 95% CI: 9, 15) pat

95 ean score, 26; 95% CI: 22, 29; P < .001) and fibroid embolization (mean score, 24; 95% CI: 21, 27; P

96 antly different from those of women awaiting fibroid embolization (mean, 16; 95% CI: 14, 18; P = .23)

97 ation at aortography performed after uterine fibroid embolization (UFE) and, using OA arteriography a

98 rates after conventional and partial uterine fibroid embolization (UFE).

99 e five women who experienced menopause after fibroid embolization had bilateral ovarian artery-to-ute

100 zation patients, and 23 (95% CI: 18, 27) for fibroid embolization patients.

101 hemoembolization for cancer; and 60, uterine fibroid embolization.

102 n 76 consecutive patients undergoing uterine fibroid embolization.

103 010, and December 27, 2010, prior to uterine fibroid embolization.

104 be used in female healthcare: contraception, fibroids, endometriosis, and certain breast cancers.

105 patient and for the percentage of individual fibroid enhancement.

106 We randomly assigned women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on

107 Some fibroids exhibited regions with partial methylene blue p

108 der, early-life risk factors for early-onset fibroids for black women were similar to those found for

109 ntaneous regression of fibroids occurs; (ii) fibroids from the same woman grow at different rates, de

110 ustrate the methodology by analyzing uterine fibroid gene expression data.

111 s that the molecular apparatus necessary for fibroid growth and development is established during tum

112 th rate; and (iv) age-related differences in fibroid growth between blacks and whites may contribute

113 Our analysis of the uterine fibroid growth gene expression data suggests that molecu

114 women less than 35 years of age had similar fibroid growth rates.

115 e ultrasound screening to detect and measure fibroids >/= 0.5 cm in diameter.

116 The majority of sampled fibroids had a strong negative correlation (Pearson's r=

117 Fibroids had an average elevated interstitial fluid pres

118 However, exposed women with fibroids had significantly larger fibroids than unexpose

119 mTOR) pathway in the pathogenesis of uterine fibroids has been suggested in several studies.

120 n physical activity and uterine leiomyomata (fibroids) has received little study, but exercise is pro

121 erved in the nonsyndromic and common form of fibroids; however, loss of heterozygosity across FH appe

122 und between isoflavone excretion and uterine fibroids; however, the intake of soy foods, the primary

123 ne fibroid study, a cross-sectional study of fibroids in 1152 premenopausal women.

124 ometry performed during the treatments of 64 fibroids in 50 women (mean age, 46.6 years +/- 4.5 [stan

125 ter retrospective analysis of 71 symptomatic fibroids in 66 women was approved by the institutional r

126 icantly improves symptoms related to uterine fibroids in 85%-90% of patients.

127 e, can be associated with the common uterine fibroids in a syndrome called multiple cutaneous and ute

128 n, manifesting as skin leiomyoma and uterine fibroids in affected individuals.

129 y has systematically evaluated the growth of fibroids in blacks and whites.

130 indicators, were associated with early-onset fibroids in blacks.

131 tions for Ms P and symptomatic patients with fibroids in general is discussed.

132 can women enrolled in a prospective study of fibroid incidence and growth (recruited 2010-2012) in th

133 been shown in Eker rats to increase uterine fibroid incidence in adulthood.

134 s, the data suggest that although incomplete fibroid infarction may not affect outcome immediately, r

135 n the outcome analysis, the 12 with complete fibroid infarction were more likely not to have enhancin

136 ssue, the true barrier to transport in these fibroids is likely high interstitial fluid pressure, cor

137 Prior evidence attributing miscarriage to fibroids is potentially biased.

138 Standard treatment of symptomatic fibroids is surgical removal by myomectomy or hysterecto

139 ns that are implicated in the progression of fibroids, is significantly enriched only in small tumors

140 Uterine fibroids (leiomyomas) are a major women's health problem

141 Uterine fibroids (leiomyomas) are the most common tumors of the

142 Uterine fibroids (leiomyomas) have historically been viewed as i

143 n's Health Study were asked about history of fibroids, medical records were obtained, and vaginal ult

144 , a 41-year-old woman with recurrent uterine fibroids, menorrhagia, anemia, and fatigue who wishes to

145 Nor were exposed women with fibroids more likely to have >/= 2 tumors than unexposed

146 lready approved for the treatment of uterine fibroids, MRgFUS is in ongoing clinical trials for the t

147 een HSV-2 seropositivity and the presence of fibroids (multivariable-adjusted odds ratio = 0.94, 95%

148 th no laparoscopic evidence of or history of fibroids (n = 1,268).

149 ted an abnormal endometrial echo (n = 14) or fibroids (n = 14).

150 ed endometrial polyps (n = 9), intracavitary fibroids (n = 3), placental polyp (n = 1), and a normal

151 5-1987) or who reported a history of uterine fibroids (n = 317).

152 Four patients developed new fibroids, none of which has caused symptoms.

153 re any associations with size of the largest fibroid, number of fibroids, or total fibroid volume.

154 Uterine fibroids occur in approximately 50% of women over the ag

155 conclude that (i) spontaneous regression of fibroids occurs; (ii) fibroids from the same woman grow

156 ivity were significantly less likely to have fibroids (odds ratio = 0.6, 95% confidence interval = 0.

157 ually unchanged after adjustment for uterine fibroids or endometriosis history.

158 itions that lead to surgery, such as uterine fibroids or endometriosis.

159 Although uterine leiomyomata (also known as fibroids or myomas) affect the reproductive health and w

160 Uterine leiomyomas (fibroids or myomas), benign tumours of the human uterus,

161 isk was marginally related to having uterine fibroids (OR=0.6, 95% CI: 0.5, 1.0) and long-term versus

162 ences in breast fibrocystic disease, uterine fibroids, or endometrial lining thickness as assessed by

163 with size of the largest fibroid, number of fibroids, or total fibroid volume.

164 embolized, leaving the large vessels of the fibroids patent.

165 The incidence of fibroids peaks in the fifth decade of age and they are m

166 mal myometrium, and that the loss of REST in fibroids permits GPR10 expression.

167 stronger association for women with multiple fibroids, possibly reflecting a stronger association for

168 Fibroid presence, number, type, and volume were assessed

169 Endovaginal ultrasounds were conducted, and fibroid presence, number, type, volume, and diameter wer

170 esults were analyzed for the total number of fibroids present in the uterus of each patient and for t

171 association between soy formula feeding and fibroid prevalence [adjusted prevalence ratio (aPR) 0.9,

172 association between soy formula feeding and fibroid prevalence and tumor number using log-binomial r

173 ould not be attributed to reverse causation (fibroids preventing exercise).

174 nd in one patient during receipt of placebo (fibroid protruding through the cervix).

175 Seven percent of fibroids regressed (>20% shrinkage).

176 Clinical success for fibroid-related symptoms was 78.6% (282 of 359).

177 When data for women who reported major fibroid-related symptoms were excluded, results remained

178 ntaining foods on the development of uterine fibroids remains to be determined.

179 ,850; 95% CI, -$31,629 to -$30,091), uterine fibroid resection (-$1509; 95% CI, -$1754 to -$1280), an

180 -37.7 days; 95% CI, -41.1 to -34.3), uterine fibroid resection (mean difference, -11.7 days; 95% CI,

181 of an IGF-I autocrine loop predicts uterine fibroid responsiveness to tamoxifen.

182 was to evaluate the relation between uterine fibroid risk and phytoestrogen exposure.

183 idence for an influence of HSV-2 exposure on fibroid risk in young African-American women.

184 evated diastolic blood pressure may increase fibroid risk through uterine smooth muscle injury, not u

185 rts have provided some support for increased fibroid risk with infant soy formula feeding in women, b

186 Racial disparities also impact fibroid risk.

187 ciation between lignan excretion and uterine fibroid risk.

188 ase in diastolic blood pressure, the risk of fibroids rose 8% (5-11%) and 10% (7-13%) among nonusers

189 T1-weighted contrast-enhancing fibroids selected for treatment had no hyperintense or h

190 The Study of Environment, Lifestyle & Fibroids (SELF) is an ongoing cohort study of 1,696 Afri

191 Both pretreatment fibroid signal intensity (SI) and posttreatment NPV pred

192 Among those with fibroids, we compared fibroid size between soy formula-exposed and unexposed w

193 es, despite a uniform hormonal milieu; (iii) fibroid size does not predict growth rate; and (iv) age-

194 tive association in individual analyses with fibroid size, type, and location but was stronger for mu

195 We prospectively tracked growth for 262 fibroids (size range: 1-13 cm in diameter) from 72 preme

196 In the group with fibroids, sonohysterography depicted small submucous fib

197 ate associations between age at menarche and fibroid status and to test for interactions with race.

198 Fibroid status was based on ultrasound screening.

199 gnancy loss in a prospective cohort in which fibroid status was uniformly documented in early pregnan

200 se interval spanning FH in the NIEHS Uterine fibroid study, a cross-sectional study of fibroids in 11

201 ter-pair families from the Finding Genes for Fibroids study.

202 new polyps in these women and 13% had fewer fibroids than in controls.

203 women fed soy formula as infants have larger fibroids than unexposed women provides further support f

204 women with fibroids had significantly larger fibroids than unexposed women with fibroids.

205 used region extended to locations within the fibroid that clearly were not heated.

206 his study intended to review HIFU in uterine fibroid therapy, to evaluate the role of HIFU in the the

207 ) differed from posttreatment ADC values for fibroid tissue (1078 mm(-6)/sec2 +/- 293) (P = .001).

208 Posttreatment ADC values for nontreated fibroid tissue (1685 mm(-6)/sec2 +/- 468) differed from

209 6) and nontreated (1437 mm(-6)/sec2 +/- 270) fibroid tissue at 6-month follow-up was observed.

210 outcome immediately, regrowth of uninfarcted fibroid tissue may result in symptom recurrence.

211 lene blue was able to passively diffuse into fibroid tissue, the true barrier to transport in these f

212 gen content and solid stress observed in the fibroid tissue.

213 myometrium and relatively little within the fibroid tissues.

214 s, nonperfused areas could extend within the fibroid to unheated areas.

215 We sought to determine the relationship of fibroids to pregnancy loss in a prospective cohort in wh

216 hese findings imply that surgical removal of fibroids to reduce risk of miscarriage deserves careful

217 Uterine fibroid treatment using HIFU was effective and safe in t

218 Surgery has been the mainstay of fibroid treatment, and various minimally invasive proced

219 Quality of life increased after all fibroid treatments.

220 The uterus frequently develops benign fibroid tumors but uterine cancers are relatively rare.

221 were aged 23-34 years and were screened for fibroids using a standardized ultrasound examination at

222 r occult tumors in common conditions such as fibroids, validation of our data in family-based studies

223 leeding (PBAC score of <75) and reduction of fibroid volume at week 13, after which patients could un

224 On average, the fibroid volume reduction at 6 months increased as the ab

225 Fibroid volume was measured by computerized analysis of

226 The median changes in total fibroid volume were -21%, -12%, and +3% (P=0.002 for the

227 argest fibroid, number of fibroids, or total fibroid volume.

228 Mean baseline ADC value in fibroids was 1504 mm(-6)/sec2 +/- 290.

229 Baseline volume of treated fibroids was 255.5 cm(3) +/- 201.7 (standard deviation),

230 Presence of fibroids was associated with miscarriage in models witho

231 No characteristic of fibroids was associated with risk.

232 Enhancement of individual fibroids was measured with quartile intervals.

233 fused portions of the incompletely infarcted fibroids was seen in three patients, two of whom had rec

234 Among those with fibroids, we compared fibroid size between soy formula-e

235 and the linked genes in nonsyndromic uterine fibroids, we explored a two-megabase interval spanning F

236 Early-onset fibroids were assessed based on self-report of a physici

237 Fibroids were classified as hyperintense or hypointense

238 UFE, only the small arterial vessels to the fibroids were embolized, leaving the large vessels of th

239 mprised women aged 17-44 years whose uterine fibroids were first visualized at the time of tubal ster

240 rs most strongly associated with early-onset fibroids were in utero diethylstilbestrol (DES; RR = 2.0

241 cant differences in endometrial thickness or fibroids were observed between the groups.

242 Uterine fibroids were used as a perfusion model.

243 outpatient procedures for women with uterine fibroids who want to conceive.

244 lly cycling premenopausal women with uterine fibroids, who were not on hormonal treatment at the time

245 teroscopic myomectomy (n = 5), a small mural fibroid with a normal cavity, which obviated surgical in

246 arger decrease in SSS than did patients with fibroids with an NPV less than 20% (50.1% +/- 19.8 vs 32

247 13.0 and 17.2% +/- 20.1, respectively) than fibroids with an NPV less than 20% or with high SI (10.7

248 ted 12-month volume reduction independently: Fibroids with an NPV of at least 20% or with low SI both

249 The trend for a reduced risk of uterine fibroids with increasing quartiles of lignan excretion w

250 Fibroids with low SI on pretreatment T2-weighted MR imag

251 determine both the size and location of the fibroids within the uterus.